Practical synthesis of a neuropeptide Y antagonist via stereoselective addition to a ketene.
[Reaction: see text]. The synthesis of neuropeptide Y antagonist 1, currently under clinical investigation for the treatment of obesity, is described. The convergent synthesis from trans-spirolactone carboxylic acid intermediate 2a and aminopyrazole 3 is predicated on a stereoselective route to the former. The coupling reaction of ethyl 4-oxocyclohexanecarboxylate (10a) with lithiated isonicotinamide 11 was investigated in detail, but even optimized conditions only provided a 45:55 ratio of trans:cis isomers (12a:12b). While selective crystallization schemes were developed to isolate the thermodynamically less stable trans isomer 2a, improved stereocontrol was subsequentially achieved by the application of ketene chemistry. The ketene formation and quench was investigated under a variety of conditions aimed at maximizing the trans:cis ratio. Reacting a mixture of carboxylic acids 2a and 2b with POCl3 in THF, followed by concomitant addition of tert-butyl alcohol in the presence of TMEDA at 35 degrees C provided a 4:1 ratio of trans:cis tert-butyl esters (18a:18b) via in situ ketene formation. Ester hydrolysis, followed by selective crystallization of undesired 2b as the HCl salt, led to isolation of 2a in 47% overall yield. Aminopyrazole intermediate 3 was synthesized via the condensation reaction of 2-fluorophenylhydrazine hydrochloride (4a) with acrylonitrile derivative 5 in 65-70% yield. Coupling of advanced intermediates 2a and 3b via activation with thionyl chloride gave a 92% yield of 1.
Iida
Takehiko
T
Process Research, Process R&D, Laboratories for Technology Development, Banyu Pharmaceutical Co., Ltd., 9-1 Kamimutsuna 3-chome, Okazaki, Aichi 444-0858 Japan. takehiko_iida@merck.com
Satoh
Hiroki
H
Maeda
Kenji
K
Yamamoto
Yuhei
Y
Asakawa
Ken-ichi
K
Sawada
Naotaka
N
Wada
Toshihiro
T
Kadowaki
Chie
C
Itoh
Takahiro
T
Mase
Toshiaki
T
Weissman
Steven A
SA
Tschaen
Dave
D
Krska
Shane
S
Volante
R P
RP
D001965:Bromides / Q000494:pharmacology; D005030:Ethylenes / Q000737:chemistry*; D007659:Ketones / Q000737:chemistry*; D018020:Lithium Compounds / Q000494:pharmacology; D015394:Molecular Structure; D009478:Neuropeptide Y / Q000037:antagonists & inhibitors* / Q000737:chemistry*; D013237:Stereoisomerism
D001965:Bromides; D005030:Ethylenes; D007659:Ketones; D018020:Lithium Compounds; D009478:Neuropeptide Y; C040949:lithium bromide; C008223:ketene